Cizzle Biotechnology Holdings PLC (GB:CIZ) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Cizzle Biotechnology Holdings PLC has partnered with Moffitt Cancer Center to utilize its CIZ1B biomarker assay in a clinical evaluation targeting the early detection of lung cancer. This collaboration marks the first instance where patients with suspicious lung nodules will be tested using Cizzle’s biomarker blood test, potentially improving accuracy in early-stage cancer diagnosis and reducing false positives from CT scans. The initiative is part of a broader strategy to establish the CIZ1B test across North America and demonstrates a significant step towards commercialization and global market entry.
For further insights into GB:CIZ stock, check out TipRanks’ Stock Analysis page.